0MSD.L - Compugroup Medical SE & Co. KGaA

LSE - LSE Delayed price. Currency in EUR
66.20
+2.20 (+3.44%)
At close: 5:50PM BST
Stock chart is not supported by your current browser
Previous close64.00
Open64.00
Bid0.00 x N/A
Ask0.00 x N/A
Day's range64.00 - 66.55
52-week range64.00 - 66.55
Volume1,427
Avg. volumeN/A
Market capN/A
Beta (5Y monthly)0.52
PE ratio (TTM)56.10
EPS (TTM)1.18
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • EQS Group

    CompuGroup Medical completes acquisition of parts of Cerner's European hospital information system business

    DGAP-News: CompuGroup Medical SE & Co. KGaA / Key word(s): Acquisition 01.07.2020 / 17:07 The issuer is solely responsible for the content of this announcement. * CompuGroup Medical completes acquisition of parts of Cerner's European hospital information system business * Acquisition of parts of the Cerner portfolio in Europe completed * CompuGroup Medical (CGM) becomes the clear number 2 in the German market for hospital information systems * Expansion of the portfolio in Spain; being one of the leading providers of HIS in public hospitals * Hospitals benefit from a combination of hospital information systems and connectivity technologies Koblenz. CompuGroup Medical SE & Co. KGaA (CGM) has acquired parts of Cerner's business in Germany and Spain. The transaction was announced in February and was completed today. The acquired parts of the company will be fully included in the group consolidation as of July 1st, 2020. CGM expects the acquired business activities to deliver a contribution to revenues and EBITDA in the second half of fiscal year 2020 above same period of prior year, including initial synergy effects. For the entire year 2019, revenues of the acquired business area were approximately EUR 74 million, and the EBITDA was at approx. EUR 13 million. Now that the transaction is complete, CGM's portfolio includes medico(R), Soarian Health Archive(R) (S-HA) and Soarian(R) Integrated Care (S-IC), which are leading hospital information systems (HIS) in Germany as well as Selene(R), a leading HIS in Spain. As a result, Koblenz-based CGM, one of the largest providers of eHealth solutions worldwide, assumes a leading position in the European HIS market. Via combination with existing solutions, in particular through better connectivity, additional value will be created for health professionals and patients."With the successful completion of this transaction, we expand our customer base for hospital information systems by more than 300 additional facilities, making us number 2 in Germany and one of the leading providers in public hospitals in Spain," explains Hannes Reichl, Managing Director Hospital Information Systems at CGM. "The combination of medico and Selene with CGM's connectivity services and the innovative CGM CLINICAL modules enables us to create significant, long-term added value for our customers. Medico and Selene customers will still be in the best hands with us in the future. We will continue to offer them their familiar software solutions and our effective service, whilst simultaneously connectivity with the other sectors in healthcare is strengthened - an important step towards universal digital support of the so-called patient journey, i.e. the accompaniment of health care throughout all stages of treatment."As a result of the takeover, around 1.5 million users, including doctors in medical practices and hospitals, dentists, pharmacists, nursing staff and many other healthcare professionals in outpatient and inpatient healthcare facilities, now rely on solutions from CompuGroup Medical. This enables comfortable, coordinated processes between the different parties involved in patient treatment.Frank Gotthardt, Founder and CEO of CGM, emphasizes: "The over 300 additional facilities that can do their important job of helping people even better thanks to intelligent digital technologies, are a good sign for the healthcare system and for everyone. We warmly welcome our approximately 300 new colleagues that bring along valuable specialist and expert knowledge. Around 6,100 employees in 18 countries are now continuously working to make our vision come true: Nobody should suffer or die just because medical information is missing somewhere at some point." About CompuGroup Medical SE & Co. KGaA CompuGroup Medical is one of the leading eHealth companies in the world. With a revenue base of EUR 746 million in 2019, its software products are designed to support all medical and organizational activities in doctors' offices, pharmacies, laboratories and hospitals. Its information services for all parties involved in the healthcare system and its web-based personal health records contribute towards safer and more efficient healthcare. CompuGroup Medical's services are based on a unique customer base of more than 1.5 million users, including doctors, dentists, pharmacists and other health professionals in inpatient and outpatient facilities. With locations in 18 countries and products in 56 countries worldwide, CompuGroup Medical is the eHealth company with one of the highest coverages among eHealth service providers. Approximately 6,100 highly qualified employees support customers with innovative solutions for the steadily growing demands of the healthcare system. Contact for media representatives: Michael Franz Head of Brand Communication P +49 (0) 261 8000-6100 F +49 (0) 261 8000-3100 E-mail: press@cgm.com Contact for analysts and investors: Claudia Thomé Head of Investor Relations P +49 (0) 261 8000-7030 F +49 (0) 261 8000-3200 E-mail: claudia.thome@cgm.com * * *01.07.2020 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.dgap.de * * * Language: English Company: CompuGroup Medical SE & Co. KGaA Maria Trost 21 56070 Koblenz Germany Phone: +49 (0)261 8000 6200 Fax: +49 (0)261 8000 3200 E-mail: investor@cgm.com Internet: www.cgm.com ISIN: DE000A288904 WKN: A28890 Indices: MDAX, TecDAX Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange EQS News ID: 1083757 End of News DGAP News Service

  • EQS Group

    CompuGroup successfully completes placement of shares over approx. EUR 341 million to finance further growth

    DGAP-News: CompuGroup Medical SE & Co. KGaA / Key word(s): Capital Increase 22.06.2020 / 23:24 The issuer is solely responsible for the content of this announcement. Press release, June 23, 2020 NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO: UNITED STATES OF AMERICA, AUSTRALIA, CANADA, JAPAN * Capital measure to strengthen equity base and support further growth successfully completed * 5,321,935 shares at EUR 64.00 each placed with international investors * Gross proceeds of approx. EUR 341 million achieved Koblenz. CompuGroup Medical SE & Co. KGaA (CGM), one of the leading eHealth companies worldwide, has successfully completed its capital measure as announced yesterday by way of an accelerated bookbuilding process ("Accelerated Bookbuilding Process") under the exclusion of the existing shareholders' subscription rights. A total of 5,321,935 shares were placed at a price of EUR 64.00 each. Gross proceeds from the placement for the Company amount to approx. EUR 341 million. "We are pleased about the trust shown by the capital market which additionally supports our positive business development", says Chief Financial Officer (CFO) Michael Rauch. The net proceeds from the capital measure shall be utilized to gain further financial strength and flexibility in order to exploit attractive growth potentials in connection with the significant opportunities offered by digitization in the healthcare sector. "Since CompuGroup Medical was founded it has successfully integrated more than 100 companies. The additional equity shall enable us to further grow organically and, if opportunities arise, continue our successful track record with M&A activities", says the company's founder and CEO Frank Gotthardt. Most recently, CompuGroup Medical had taken over the French software provider EPSILOG and had created further foundations for the growth and development of new regional markets by the acquisition of the German and Spanish IT Healthcare portfolios of Cerner as announced on 5 February 2020. About CompuGroup Medical SE & Co. KGaA CompuGroup Medical is one of the leading eHealth companies in the world. With a revenue base of EUR 746 million in 2019, its software products are designed to support all medical and organizational activities in doctors' offices, pharmacies, laboratories and hospitals. Its information services for all parties involved in the healthcare system and its web-based personal health records contribute towards safer and more efficient healthcare. CompuGroup Medical's services are based on a unique customer base of more than 1 million users, including doctors, dentists, pharmacists and other health professionals in inpatient and outpatient facilities. With locations in 18 countries and products in 56 countries worldwide, CompuGroup Medical is the eHealth company with one of the highest coverages among eHealth service providers. Approximately 5,800 highly qualified employees support customers with innovative solutions for the steadily growing demands of the healthcare system. Important information This announcement and the information contained herein are not intended for, and should not be made available to, any person in the United States of America (the "United States"), Australia, Canada or Japan or any other jurisdiction in which such publication, disclosure or distribution would be unlawful. This announcement does not constitute an offer, or part of an offer, or a solicitation to purchase securities in the United States, Australia, Canada, Japan, or any other jurisdiction, whether or not such offer or solicitation to make an offer would be unlawful. This document is not an offer of securities for sale in the United States. The shares of CompuGroup Medical SE & Co. KGaA (the "Shares") have not been registered and will not be registered under the U.S. Securities Act of 1933, as amended (the "Securities Act"), and may not be offered or sold in the United States unless registered under the Securities Act or pursuant to an exemption from such registration. A public offering and/or a registration under the Securities Act are not intended. This document is only being distributed to and is only directed at persons who (i) are outside the United Kingdom or (ii) are investment professionals falling within Article 19(5) or persons falling within Article 49(2)(a) to (d) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (all such persons together being referred to as "Relevant Persons"). The Shares are only available to, and any invitation, offer or agreement to subscribe, purchase or otherwise acquire such securities will be engaged in only with, Relevant Persons. This announcement is directed only at Relevant Persons and must not be acted on or relied on by persons who are not Relevant Persons. This release may contain "forward-looking statements" or statements that are considered to be forward-looking. Such forward-looking statements may be identified by the use of corresponding words such as "believe", "assume", "plan", "forecast", "expect", "intend", "may", "could", "will" or "should" or their respective negations or other variations or similar words. The same applies to statements regarding strategies, plans, objectives, future events or intentions. Forward-looking statements may differ significantly from future results and often in fact differ. All forward-looking statements reflect CompuGroup Medical SE & Co. KGaA's current view of future events and are subject to risks relating to future events and other risks, uncertainties and assumptions regarding CompuGroup Medical SE & Co. KGaA's business, financial position, results of operations, liquidity, prospects, growth or strategy. Forward-looking statements should always be considered from the perspective of the date on which they are made. CompuGroup Medical SE & Co. KGaA as well as the placing credit institutions and their respective affiliated companies expressly disclaim any obligation to update, review or adjust any forward-looking statements contained in this release as a result of new information, future developments or other reasons. Contact for media representatives: Michael Franz Head of Brand Communication T +49 (0) 261 8000-6100 F +49 (0) 261 8000-3100 E-Mail: presse@cgm.com Contact for analysts and investors: Claudia Thomé Head of Investor Relations T +49 (0) 261 8000-7030 F +49 (0) 261 8000-3200 E-Mail: claudia.thome@cgm.com * * *22.06.2020 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.dgap.de * * * Language: English Company: CompuGroup Medical SE & Co. KGaA Maria Trost 21 56070 Koblenz Germany Phone: +49 (0)261 8000 6200 Fax: +49 (0)261 8000 3200 E-mail: investor@cgm.com Internet: www.cgm.com ISIN: DE000A288904 WKN: A28890 Indices: MDAX, TecDAX Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange EQS News ID: 1076117 End of News DGAP News Service

  • EQS Group

    CompuGroup Medical SE & Co. KGaA: Successful placement of cash capital increase and treasury shares - gross proceeds of approx. EUR 341 million

    CompuGroup Medical SE & Co. KGaA / Key word(s): Transaction in Own Shares/Capital Increase CompuGroup Medical SE & Co. KGaA: Successful placement of cash capital increase and treasury shares - gross proceeds of approx. EUR 341 million 22-Jun-2020 / 23:00 CET/CEST Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. * * *NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO: UNITED STATES OF AMERICA, AUSTRALIA, CANADA, JAPANCompuGroup Medical SE & Co. KGaA successfully placed the capital measure resolved on 22 June 2020. The gross proceeds of the placement amount to approx. EUR 341 million.In the course of the capital measure, a total of 5,321,935 shares were placed to qualified investors by way of an accelerated bookbuilding process at a placement price of 64.00 EUR each.By virtue of the capital increase which was resolved in the course of the capital measure the share capital of the Company will increase from EUR 53,219,350 to EUR 53,734,576. The new shares are entitled to dividends as of 1 January 2020 and will be included in the existing listing of the regulated market as well as simultaneously in the sub-segment of the regulated market (Prime Standard) on the Frankfurt Stock Exchange. The placed shares attributable to the capital increase were initially made available for the purpose of implementing the transaction by way of a share loan, free of charge, granted by GT1 Vermögensverwaltung GmbH, the investment company of the major shareholder Mr Frank Gotthardt.The net proceeds from the capital measure serve to strengthen the equity base of CompuGroup Medical-Group and provide financial flexibility to continue its growth strategy.Contact:Claudia Thomé Head of Investor Relations CompuGroup Medical SE & Co. KGaA Email: claudia.thome@cgm.com Tel +49 261 8000 7030 Important informationThis announcement and the information contained herein are not intended for, and should not be made available to, any person in the United States of America (the "United States"), Australia, Canada or Japan or any other jurisdiction in which such publication, disclosure or distribution would be unlawful.This announcement does not constitute an offer, or part of an offer, or a solicitation to purchase securities in the United States, Australia, Canada, Japan, or any other jurisdiction, whether or not such offer or solicitation to make an offer would be unlawful. This document is not an offer of securities for sale in the United States. The shares of CompuGroup Medical SE & Co. KGaA (the "Shares") have not been registered and will not be registered under the U.S. Securities Act of 1933, as amended (the "Securities Act"), and may not be offered or sold in the United States unless registered under the Securities Act or pursuant to an exemption from such registration. A public offering and/or a registration under the Securities Act are not intended.This document is only being distributed to and is only directed at persons who (i) are outside the United Kingdom or (ii) are investment professionals falling within Article 19(5) or persons falling within Article 49(2)(a) to (d) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (all such persons together being referred to as "Relevant Persons"). The Shares are only available to, and any invitation, offer or agreement to subscribe, purchase or otherwise acquire such securities will be engaged in only with, Relevant Persons. This announcement is directed only at Relevant Persons and must not be acted on or relied on by persons who are not Relevant Persons.This release may contain "forward-looking statements" or statements that are considered to be forward-looking. Such forward-looking statements may be identified by the use of corresponding words such as "believe", "assume", "plan", "forecast", "expect", "intend", "may", "could", "will" or "should" or their respective negations or other variations or similar words. The same applies to statements regarding strategies, plans, objectives, future events or intentions. Forward-looking statements may differ significantly from future results and often in fact differ. All forward-looking statements reflect CompuGroup Medical SE & Co. KGaA's current view of future events and are subject to risks relating to future events and other risks, uncertainties and assumptions regarding CompuGroup Medical SE & Co. KGaA's business, financial position, results of operations, liquidity, prospects, growth or strategy. Forward-looking statements should always be considered from the perspective of the date on which they are made. CompuGroup Medical SE & Co. KGaA as well as the placing credit institutions and their respective affiliated companies expressly disclaim any obligation to update, review or adjust any forward-looking statements contained in this release as a result of new information, future developments or other reasons.* * *22-Jun-2020 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.dgap.de * * * Language: English Company: CompuGroup Medical SE & Co. KGaA Maria Trost 21 56070 Koblenz Germany Phone: +49 (0)261 8000 6200 Fax: +49 (0)261 8000 3200 E-mail: investor@cgm.com Internet: www.cgm.com ISIN: DE000A288904 WKN: A28890 Indices: MDAX, TecDAX Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange EQS News ID: 1076111 End of Announcement DGAP News Service

  • EQS Group

    CompuGroup Medical SE & Co. KGaA resolves placement of treasury shares and cash capital increase from authorised capital

    CompuGroup Medical SE & Co. KGaA / Key word(s): Transaction in Own Shares/Capital Increase CompuGroup Medical SE & Co. KGaA resolves placement of treasury shares and cash capital increase from authorised capital 22-Jun-2020 / 17:46 CET/CEST Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. * * *NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO: UNITED STATES OF AMERICA, AUSTRALIA, CANADA, JAPAN Today the General Partner of CompuGroup Medical SE & Co. KGaA (the Company) resolved, with the approval of the Supervisory Board and the Joint Committee of the Company, to increase the share capital of the Company (ISIN: DE000A288904) by up to 515,226 new shares (approx. 0.97% of current share capital) and to sell up to 4,806,709 treasury shares of the Company (approx. 9.03% of current share capital). The subscription right of the shareholders is excluded pursuant to Section 186 (3) Sentence 4 in conjunction with Section 278 (3) of the German Stock Corporation Act.The capital increase will be carried out against contribution in cash and by partial utilisation of the authorised capital provided for under Section 4 (3) of the Company's articles of association. The share capital of the Company shall be increased from EUR 53,219,350 to up to 53,734,576 EUR by issuance of up to 515,226 new registered non-par value shares. The new shares carry the same rights as the existing shares and are entitled to dividends for the fiscal year 2020. Following their issuance they will be included in the existing listing of the regulated market as well as simultaneously in the sub-segment of the regulated market with additional post-admission obligations (Prime Standard) on the Frankfurt Stock Exchange. The sale of treasury shares will also be carried out against cash consideration.Therefore, in the course of the capital measure, a total of up to 5,321,935 shares will be offered in an international private placement exclusively to qualified investors by way of an accelerated bookbuilding process ("Accelerated Bookbuilding"), which will commence directly after the publication of this release. The order book will presumably close on 23 June 2020 before the opening of trading, although the Company reserves the right to close the order book at any earlier time. The placement price and the exact number of shares placed will be determined following completion of the placement process. In order to ensure a timely delivery to the investors participating in the offer, GT1 Vermögensverwaltung GmbH, the investment company of the major shareholder Mr Frank Gotthardt, makes available to the placing credit institutions by way of a share loan free of charge and until the registration of the capital increase with the commercial register a number of shares corresponding to the capital increase for the purpose of the placement.The Company has agreed to a lock-up of 90 days, subject to market standard exemptions.The expected net proceeds from the capital measure serve to strengthen the equity base of CompuGroup Medical-Group and provide it with financial flexibility for the implementation of its strategy to further organically and, if opportunities arise, dynamically grow through mergers and acquisitions. Contact:Claudia Thomé Head of Investor Relations CompuGroup Medical SE & Co. KGaA Email: claudia.thome@cgm.com Tel +49 261 8000 7030 Tel +49 261 8000 6200Important informationThis announcement and the information contained herein are not intended for, and should not be made available to, any person in the United States of America (the "United States"), Australia, Canada or Japan or any other jurisdiction in which such publication, disclosure or distribution would be unlawful.This announcement does not constitute an offer, or part of an offer, or a solicitation to purchase securities in the United States, Australia, Canada, Japan, or any other jurisdiction, whether or not such offer or solicitation to make an offer would be unlawful. This document is not an offer of securities for sale in the United States. The shares of CompuGroup Medical SE & Co. KGaA (the "Shares") have not been registered and will not be registered under the U.S. Securities Act of 1933, as amended (the "Securities Act"), and may not be offered or sold in the United States unless registered under the Securities Act or pursuant to an exemption from such registration. A public offering and/or a registration under the Securities Act are not intended.This document is only being distributed to and is only directed at persons who (i) are outside the United Kingdom or (ii) are investment professionals falling within Article 19(5) or persons falling within Article 49(2)(a) to (d) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (all such persons together being referred to as "Relevant Persons"). The Shares are only available to, and any invitation, offer or agreement to subscribe, purchase or otherwise acquire such securities will be engaged in only with, Relevant Persons. This announcement is directed only at Relevant Persons and must not be acted on or relied on by persons who are not Relevant Persons.This release may contain "forward-looking statements" or statements that are considered to be forward-looking. Such forward-looking statements may be identified by the use of corresponding words such as "believe", "assume", "plan", "forecast", "expect", "intend", "may", "could", "will" or "should" or their respective negations or other variations or similar words. The same applies to statements regarding strategies, plans, objectives, future events or intentions. Forward-looking statements may differ significantly from future results and often in fact differ. All forward-looking statements reflect CompuGroup Medical SE & Co. KGaA's current view of future events and are subject to risks relating to future events and other risks, uncertainties and assumptions regarding CompuGroup Medical SE & Co. KGaA's business, financial position, results of operations, liquidity, prospects, growth or strategy. Forward-looking statements should always be considered from the perspective of the date on which they are made. CompuGroup Medical SE & Co. KGaA as well as the placing credit institutions and their respective affiliated companies expressly disclaim any obligation to update, review or adjust any forward-looking statements contained in this release as a result of new information, future developments or other reasons.* * *22-Jun-2020 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.dgap.de * * * Language: English Company: CompuGroup Medical SE & Co. KGaA Maria Trost 21 56070 Koblenz Germany Phone: +49 (0)261 8000 6200 Fax: +49 (0)261 8000 3200 E-mail: investor@cgm.com Internet: www.cgm.com ISIN: DE000A288904 WKN: A28890 Indices: MDAX, TecDAX Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange EQS News ID: 1075529 End of Announcement DGAP News Service

  • EQS Group

    CompuGroup Medical lays foundation for further growth with conversion into new legal form

    DGAP-News: CompuGroup Medical SE & Co. KGaA / Key word(s): Miscellaneous 18.06.2020 / 12:41 The issuer is solely responsible for the content of this announcement. * Change of legal form into a KGaA is now effective after entry in the commercial register * New legal form enables more flexible financing of growth course with high personnel continuity * Philipp von Ilberg is the Chairman of the newly-formed Supervisory Board * Stock exchange listing as a KGaA and registered shares from Monday, June 22, 2020Koblenz. CompuGroup Medical (CGM), one of the leading eHealth companies in the world, is now operating as a partnership limited by shares (KGaA). The change of legal form from a European Company (SE) into a KGaA became effective today after it was entered in the commercial register at the Lower Court of Koblenz. "The conversion into a KGaA gives us the greatest possible flexibility to secure our growth ambitions and solid value development. At the same time, the Gotthardt family will remain as anchor shareholders, fostering the entrepreneurial perspective and maintaining the founder's spirit," explains Chief Financial Officer (CFO) Michael Rauch.Philipp von Ilberg (57) was elected as Chairman of the Supervisory Board. He worked as a lawyer for various renowned law firms. The previous Chairman of the Supervisory Board, Dr. Klaus Esser, moves as Vice Chairman to the Administrative Board of CompuGroup Medical Management SE, the general partner of CompuGroup Medical SE & Co. KGaA. The Administrative Board further comprises of the company's founder Frank Gotthardt as Chairman and Prof. Dr. Daniel Gotthardt.To ensure the greatest possible continuity in the company management, the previous members of the Management Board were appointed as Managing Directors of CompuGroup Medical Management SE. The management thus continuously includes the previous members of the Management Board of CompuGroup Medical SE, namely Frank Gotthardt (Chairman of the Management and CEO), Frank Brecher (Managing Director Process and Efficiency Management), Dr. Ralph Körfgen (Managing Director Ambulatory & Pharmacy Information Systems), Dr. Eckart Pech (Managing Director Consumer and Health Management Information Systems), Michael Rauch (Chief Financial Officer) and Hannes Reichl (Managing Director Hospital Information Systems)."My family and I will continue to always stand up for what has made CompuGroup Medical successful", emphasizes Frank Gotthardt. "We stand for consistent customer orientation, for great entrepreneurial drive, for determined growth and for this fundamental vision: Nobody should suffer or die just because at some point medical information was missing."The change of legal form will be completed on the stock exchange on Monday, June 22, 2020. From this day, the company will be listed on the stock exchange as a KGaA. The shares in CompuGroup Medical SE & Co. KGaA will no longer be bearer shares, but registered shares. This will make it easier for the company in the future to get in direct contact with its shareholders. The former bearer shares of CompuGroup Medical SE will be traded for the last time on Friday, June 19, 2020. The inclusion of the shares of the company into TecDAX and MDAX remains unchanged. The ordinary general meeting of CompuGroup Medical SE resolved on the change of legal form on May 13, 2020, by a large majority.About CompuGroup Medical SE & Co. KGaA CompuGroup Medical is one of the leading eHealth companies in the world. With a revenue base of EUR 746 million in 2019, its software products are designed to support all medical and organizational activities in doctors' offices, pharmacies, laboratories and hospitals. Its information services for all parties involved in the healthcare system and its web-based personal health records contribute towards safer and more efficient healthcare. CompuGroup Medical's services are based on a unique customer base of more than 1 million users, including doctors, dentists, pharmacists and other health professionals in inpatient and outpatient facilities. With locations in 18 countries and products in 56 countries worldwide, CompuGroup Medical is the eHealth company with one of the highest coverages among eHealth service providers. Approximately 5,800 highly qualified employees support customers with innovative solutions for the steadily growing demands of the healthcare system.Contact for media representatives: Michael Franz Head of Brand Communication P +49 (0) 261 8000-6100 F +49 (0) 261 8000-3100 E-mail: press@cgm.com Contact for analysts and investors: Claudia Thomé Head of Investor Relations P +49 (0) 261 8000-7030 F +49 (0) 261 8000-3200 E-mail: claudia.thome@cgm.com Web: www.cgm.com You can reach our press archive at: Press releases CGM Group: https://www.cgm.com/corp/presse/presseinformationen/Presse.en.jsp * * *18.06.2020 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.dgap.de * * * Language: English Company: CompuGroup Medical SE & Co. KGaA Maria Trost 21 56070 Koblenz Germany Phone: +49 (0)261 8000 6200 Fax: +49 (0)261 8000 3200 E-mail: investor@cgm.com Internet: www.cgm.com ISIN: DE0005437305 WKN: 543730 Indices: MDAX, TecDAX Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange EQS News ID: 1073545 End of News DGAP News Service

  • Can Compugroup Medical Se ride out the Covid-19 economic shock?
    Stockopedia

    Can Compugroup Medical Se ride out the Covid-19 economic shock?

    Economic shockwaves caused by Covid-19 have plunged stock markets into turmoil, but some shares are better able to absorb this volatility than others - and Com8230;

  • EQS Group

    CompuGroup Medical SE: Annual General Meeting approves change of legal form into a partnership limited by shares (Kommanditgesellschaft auf Aktien, KGaA) and dividend at previous year's level

    DGAP-News: CompuGroup Medical SE / Key word(s): AGM/EGM 13.05.2020 / 17:03 The issuer is solely responsible for the content of this announcement. Koblenz. CompuGroup Medical SE, one of the leading eHealth companies worldwide, held its Annual General Meeting, virtually, today for the first time. This became necessary due to the social distancing regulations in place as a result of the COVID-19 pandemic, which continue to apply. With a majority of 75.67 %, the shareholders of the MDAX company decided to change its legal form into a partnership limited by shares (Kommanditgesellschaft auf Aktien, KGaA). This gives the company additional flexibility in financing future growth and continues to bind the Gotthardt family closely to the company as reliable anchor shareholders.Frank Gotthardt, Chairman of the Management Board and CEO, founded today's CompuGroup Medical SE in 1987 and has since then been at the helm of the company, the shares of which are traded in the MDAX since September 2019. "I am pleased that a vast majority of shareholders followed the proposal of the Management Board and the Supervisory Board today, and I wish to thank all of the shareholders for their trust," emphasizes Frank Gotthardt. "We will continue on our consistent growth course of the past years. Following this change of legal form, we are firmly determined to be even more successful in taking advantage of the enormous opportunities offered by digitization in the healthcare sector for the benefit of all.""The past few weeks, with the dramatic developments during the global COVID-19 pandemic, have shown the great potential that digitization has in the healthcare system," continued Frank Gotthardt. "Video consultations, telemonitoring and electronic patient files are just a few of the applications that bring real added value beyond the current crisis situation. In the current Corona crisis, these applications protect patients, doctors and everyone else who works in the healthcare sector." This is exactly what the high demand for digital solutions shows. Over the past two months approximately 80,000 new customers registered for the CGM video consultation - a quantum leap.All items on the agenda were adopted in the virtual Annual General Meeting with the required majority. Among other things, CompuGroup Medical SE will pay a dividend of EUR 0.50 per share, which is at the previous year's level.As part of the change of legal form, a monistically structured European Stock Corporation (Societas Europaea, SE), CompuGroup Medical Management SE, will join the future CompuGroup Medical SE & Co. KGaA as its general partner. CompuGroup Medical Management SE is indirectly held by Mr. Frank Gotthardt as controlling shareholder. The Administrative Board of CompuGroup Medical Management SE consists of Mr. Frank Gotthardt (Chairman), Dr. Klaus Esser (Deputy Chairman) and Prof. Dr. Daniel Gotthardt.The change of legal form does not change the participation of the shareholders in the company. They will hold the same number of shares in KGaA as they hold in CompuGroup Medical SE prior to the change of legal form. The aggregate number of shares issued will also remain unchanged. However, the shares of the future KGaA will be registered shares as opposed to the current bearer shares. The change of legal form will become effective upon registration with the commercial register.The Supervisory Board of CompuGroup Medical SE & Co. KGaA will comprise of six shareholder representatives and the same number of employee representatives. Mr. Philipp von Ilberg, Dr. Ulrike Handel, Dr. Bettina Volkens, Mr. Matthias Störmer, Prof. Dr. Martin Köhrmann as well as Dr. Michael Fuchs were elected to the Supervisory Board as shareholder representatives. The election of the employee representatives to the Supervisory Board will take place in accordance with the legal regulations after registration of the change of form with the commercial register.Until entry in the commercial register, the current Supervisory Board of CompuGroup Medical SE will remain in force. With a large majority, the shareholders re-elected the four current shareholder representatives for the Supervisory Board, whose term of office ended at the end of the Annual General Meeting. Dr. Klaus Esser is to remain the Chairman of the Supervisory Board. Prof. Dr. Daniel Gotthardt, Dr. Ulrike Handel and Mr. Thomas Seifert were also re-elected to the Supervisory Board.About CompuGroup Medical SE CompuGroup Medical is one of the leading eHealth companies in the world. With a revenue base of EUR 746 million in 2019, its software products are designed to support all medical and organizational activities in doctors' offices, pharmacies, laboratories and hospitals. Its information services for all parties involved in the healthcare system and its web-based personal health records contribute towards safer and more efficient healthcare. CompuGroup Medical's services are based on a unique customer base of more than 1 million users, including doctors, dentists, pharmacists and other health professionals in inpatient and outpatient facilities. With locations in 18 countries and products in 56 countries worldwide, CompuGroup Medical is the eHealth company with one of the highest coverages among eHealth service providers. Approximately 5,800 highly qualified employees support customers with innovative solutions for the steadily growing demands of the healthcare system.You can reach our press archive at: Press releases CGM Group: https://www.cgm.com/corp/presse/presseinformationen/Presse.en.jsp CompuGroup Medical SE Contact for media representatives: Michael Franz Head of Brand Communication P +49 (0) 261 8000-6100 F +49 (0) 261 8000-3100 E-mail: press@cgm.com Contact for analysts and investors: Claudia Thomé Head of Investor Relations P +49 (0) 261 8000-7030 F +49 (0) 261 8000-3200 E-mail: claudia.thome@cgm.com Web: www.cgm.com Social media: Visit us on Twitter, LinkedIn and XING * * *13.05.2020 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.dgap.de * * * Language: English Company: CompuGroup Medical SE Maria Trost 21 56070 Koblenz Germany Phone: +49 (0)261 8000 6200 Fax: +49 (0)261 8000 3200 E-mail: investor@cgm.com Internet: www.cgm.com ISIN: DE0005437305 WKN: 543730 Indices: MDAX, TecDAX Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange EQS News ID: 1044151 End of News DGAP News Service

  • EQS Group

    CompuGroup Medical SE: Annual General Meeting approves the change of legal form into a partnership limited by shares (Kommanditgesellschaft auf Aktien, KGaA)

    CompuGroup Medical SE / Key word(s): AGM/EGM CompuGroup Medical SE: Annual General Meeting approves the change of legal form into a partnership limited by shares (Kommanditgesellschaft auf Aktien, KGaA) 13-May-2020 / 15:49 CET/CEST Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. * * *The Annual General Meeting of CompuGroup Medical SE of today has approved the change of legal form of the company, as proposed by the Management Board and the Supervisory Board, into a partnership limited by shares (Kommanditgesellschaft auf Aktien, KGaA) under the name "CompuGroup Medical SE & Co. KGaA". The general partner is CompuGroup Medical Management SE, a monistically structured European Stock Corporation (Societas Europaea, SE), which is held by the founder of the company and Chairman of the Management Board, Mr. Frank Gotthardt, as the controlling shareholder.The participation of the shareholders in the company will not change as a result of the change of legal form. They will hold the same number of no-par value shares in the KGaA as they hold today, prior to the change of legal form, in CompuGroup Medical SE. The aggregate number of shares issued will also remain unchanged. The change of legal form will become effective upon registration with the commercial register. Contact: Claudia Thomé Head of Investor Relations CompuGroup Medical SE email: claudia.thome@cgm.com phone +49 261 8000 7030 phone +49 261 8000 6200 * * *13-May-2020 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.dgap.de * * * Language: English Company: CompuGroup Medical SE Maria Trost 21 56070 Koblenz Germany Phone: +49 (0)261 8000 6200 Fax: +49 (0)261 8000 3200 E-mail: investor@cgm.com Internet: www.cgm.com ISIN: DE0005437305 WKN: 543730 Indices: MDAX, TecDAX Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange EQS News ID: 1044021 End of Announcement DGAP News Service

  • What Is CompuGroup Medical Societas Europaea's (ETR:COP) P/E Ratio After Its Share Price Rocketed?
    Simply Wall St.

    What Is CompuGroup Medical Societas Europaea's (ETR:COP) P/E Ratio After Its Share Price Rocketed?

    CompuGroup Medical Societas Europaea (ETR:COP) shareholders are no doubt pleased to see that the share price has had a...

  • Can You Imagine How CompuGroup Medical Societas Europaea's (ETR:COP) Shareholders Feel About The 81% Share Price Increase?
    Simply Wall St.

    Can You Imagine How CompuGroup Medical Societas Europaea's (ETR:COP) Shareholders Feel About The 81% Share Price Increase?

    CompuGroup Medical Societas Europaea (ETR:COP) shareholders might be concerned after seeing the share price drop 23...

  • Here’s What CompuGroup Medical Societas Europaea’s (ETR:COP) Return On Capital Can Tell Us
    Simply Wall St.

    Here’s What CompuGroup Medical Societas Europaea’s (ETR:COP) Return On Capital Can Tell Us

    Today we are going to look at CompuGroup Medical Societas Europaea (ETR:COP) to see whether it might be an attractive...

  • Is CompuGroup Medical Societas Europaea (ETR:COP) A Smart Choice For Dividend Investors?
    Simply Wall St.

    Is CompuGroup Medical Societas Europaea (ETR:COP) A Smart Choice For Dividend Investors?

    Today we'll take a closer look at CompuGroup Medical Societas Europaea (ETR:COP) from a dividend investor's...

  • Can CompuGroup Medical Societas Europaea (ETR:COP) Maintain Its Strong Returns?
    Simply Wall St.

    Can CompuGroup Medical Societas Europaea (ETR:COP) Maintain Its Strong Returns?

    While some investors are already well versed in financial metrics (hat tip), this article is for those who would like...

  • If You Like EPS Growth Then Check Out CompuGroup Medical Societas Europaea (ETR:COP) Before It's Too Late
    Simply Wall St.

    If You Like EPS Growth Then Check Out CompuGroup Medical Societas Europaea (ETR:COP) Before It's Too Late

    Like a puppy chasing its tail, some new investors often chase 'the next big thing', even if that means buying 'story...

  • Is CompuGroup Medical Societas Europaea (ETR:COP) Excessively Paying Its CEO?
    Simply Wall St.

    Is CompuGroup Medical Societas Europaea (ETR:COP) Excessively Paying Its CEO?

    In 2008 Frank Gotthardt was appointed CEO of CompuGroup Medical Societas Europaea (ETR:COP). This analysis aims first...

  • Here's What CompuGroup Medical Societas Europaea's (ETR:COP) P/E Is Telling Us
    Simply Wall St.

    Here's What CompuGroup Medical Societas Europaea's (ETR:COP) P/E Is Telling Us

    Today, we'll introduce the concept of the P/E ratio for those who are learning about investing. We'll look at...

  • Could The CompuGroup Medical Societas Europaea (ETR:COP) Ownership Structure Tell Us Something Useful?
    Simply Wall St.

    Could The CompuGroup Medical Societas Europaea (ETR:COP) Ownership Structure Tell Us Something Useful?

    If you want to know who really controls CompuGroup Medical Societas Europaea (ETR:COP), then you'll have to look at...

  • Are CompuGroup Medical Societas Europaea’s Returns On Capital Worth Investigating?
    Simply Wall St.

    Are CompuGroup Medical Societas Europaea’s Returns On Capital Worth Investigating?

    Today we'll look at CompuGroup Medical Societas Europaea (ETR:COP) and reflect on its potential as an investment...

  • Is CompuGroup Medical Societas Europaea (ETR:COP) A Risky Investment?
    Simply Wall St.

    Is CompuGroup Medical Societas Europaea (ETR:COP) A Risky Investment?

    Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...

  • How Does CompuGroup Medical Societas Europaea (FRA:COP) Stand Up To These Simple Dividend Safety Checks?
    Simply Wall St.

    How Does CompuGroup Medical Societas Europaea (FRA:COP) Stand Up To These Simple Dividend Safety Checks?

    Could CompuGroup Medical Societas Europaea (FRA:COP) be an attractive dividend share to own for the long haul...

  • Here's What CompuGroup Medical Societas Europaea's (FRA:COP) P/E Is Telling Us
    Simply Wall St.

    Here's What CompuGroup Medical Societas Europaea's (FRA:COP) P/E Is Telling Us

    This article is written for those who want to get better at using price to earnings ratios (P/E ratios). We'll apply a...

By using Yahoo, you agree that we and our partners can use cookies for purposes such as customising content and advertising. See our Privacy Policy to learn more